BioVersys is strengthening its executive management team with the arrival of Matthias Werder as Chief Financial Officer as of November 1st, 2018. He will lead finance, human resources, legal and support the CEO in fundraising and corporate strategy.
With more than 20 years of international experience, he brings important hands-on fundraising, investment, CFO and COO experience. In healthcare, Matthias has provided transaction advice, executed major M&A transactions for private equity investors and supported fundraising activities for high growth, early stage companies, and audited well regarded stock quoted companies, the WHO and the Global Fund. Matthias is a Chartered Financial Analyst (CFA), Fellow Chartered Accountant and holds a master’s in economics from the University of St. Gallen, Switzerland.
Matthias Werder, a Swiss national, brings extensive private equity experience and broad knowledge of the investor market. Matthias’ prime mission will be to help BioVersys to further develop its investor base in a series B financing round.
Dr. Marc Gitzinger, CEO and co-founder of BioVersys: “We are delighted that Matthias has joined BioVersys during this important time in the company’s development, as we move our candidate molecules through late stage preclinical development and prepare to initiate first Phase I clinical trials in the 2H 2019. Matthias brings significant experience as an already established CFO with transaction-based expertise in many sectors including healthcare, and a broad network that will help BioVersys to grow and further develop our corporate strategy”.
Matthias comments: “I am excited to join BioVersys, an innovative, fast growing biotech company that is taking exciting steps towards soon being a clinical stage company with its own development projects in the area of high unmet medical need of antimicrobial resistance, where patients’ lives continue to be at risk from a lack of innovative and effective treatment options.”